US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
USOTC
BAIC MTR Corporation Ltd (PK) (BCCMY) 銘柄情報

BAIC MTR Corporation Ltd (PK) (BCCMY)

1.135

0.00

(0.00%)

終了 7月12日 5:00AM

BAIC MTR Corporation Ltd (PK) (BCCMY) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

1.135

( - )

買値

0.9603

売値

1.14

出来高

-

平均取引量 (3 か月)

US$ 7,031,847

財務取引量

-

0.00 日の範囲 0.00

1.135 52 週間の範囲 2.96

時価総額

企業価値

22.064B

前日終値

1.135

始値

-

時刻

最終取引時間

VWAP

-

歳入

153.01B

純利益

-1.64B

発行済株式数

8,015,338,182

浮動株比率 (%)

21.89%

機関投資家保有比率 (%)

4.28%

配当利回り

PER

-3.57

株価売上高倍率 (PSR)

0.04

1 株当たり利益 (EPS)

-0.2

ベータ

0.46

BAIC Motor Corporation Limited, together with its subsidiaries, engages in the research and development, manufacture, sale, and after-sale service of passenger vehicles in the People’s Republic of China. It also offers engines, powertrains, power batteries, and other core parts and components for pa... BAIC Motor Corporation Limited, together with its subsidiaries, engages in the research and development, manufacture, sale, and after-sale service of passenger vehicles in the People’s Republic of China. It also offers engines, powertrains, power batteries, and other core parts and components for passenger vehicles, as well as range extenders, transmissions, and new energy reducers. In addition, the company is involved in car financing and automobile aftermarket-related activities. It sells its products under the Beijing Brand, Beijing Benz, Beijing Hyundai, and Fujian Benz brand names. The company was founded in 1958 and is headquartered in Beijing, the People’s Republic of China. 詳細を表示

セクター

-

業界

-

ウェブサイト

www.baicmotor.com

本社

Beijing, China

設立

2026

BAIC MTR Corporation Ltd (PK) is listed in the sector of the その他OTC with ticker BCCMY. The last closing price for BAIC MTR (PK) was US$1.14. Over the last year, BAIC MTR (PK) shares have traded in a share price range of US$ 1.135 to US$ 2.96.

BAIC MTR (PK) currently has 8,015,338,182 shares in issue. The market capitalisation of BAIC MTR (PK) is US$9.10 billion. BAIC MTR (PK) has a price to earnings ratio (PE ratio) of -3.57.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	1.135	1.135	1.135	214	1.135	DR
12	-0.615	-35.1428571429	1.75	1.75	1.135	2635	1.59378515	DR
26	-1.325	-53.8617886179	2.46	2.5	1.135	1645	1.64942218	DR
52	-1.515	-57.1698113208	2.65	2.96	1.135	837	1.77888653	DR
156	-1.385	-54.9603174603	2.52	3.25	1.135	739	2.29429165	DR
260	-2.565	-69.3243243243	3.7	4.73	1.135	618	2.50074041	DR

BCCMY - Frequently Asked Questions (FAQ)

What is the current BAIC MTR Corporation Ltd (PK) share price?

The current share price of BAIC MTR Corporation Ltd (PK) is US$ 1.135

How many BAIC MTR Corporation Ltd (PK) shares are in issue?

BAIC MTR Corporation Ltd (PK) has 8,015,338,182 shares in issue

What is the market cap of BAIC MTR Corporation Ltd (PK)?

The market capitalisation of BAIC MTR Corporation Ltd (PK) is USD 9.1B

What is the 1 year trading range for BAIC MTR Corporation Ltd (PK) share price?

BAIC MTR Corporation Ltd (PK) has traded in the range of US$ 1.135 to US$ 2.96 during the past year

What is the PE ratio of BAIC MTR Corporation Ltd (PK)?

The price to earnings ratio of BAIC MTR Corporation Ltd (PK) is -3.57

What is the cash to sales ratio of BAIC MTR Corporation Ltd (PK)?

The cash to sales ratio of BAIC MTR Corporation Ltd (PK) is 0.04

What is the registered address of BAIC MTR Corporation Ltd (PK)?

The registered address for BAIC MTR Corporation Ltd (PK) is No. 99 Shuanghe Street, Beijing, 101300

What is the BAIC MTR Corporation Ltd (PK) website address?

The website address for BAIC MTR Corporation Ltd (PK) is www.baicmotor.com

BlueSky195

BlueSky195 1分前

You don’t have a clue what is really going on, quit spewing your wild guess's. Watcher too, just stop with your rambling speculations.

Truthsocial

Truthsocial 2分前

Current Status and Next Steps
Vivos Inc. received FDA Investigational Device Exemption (IDE) approval for its RadioGel study on July 6, 2026. This clearance allows the company to initiate its first-in-human feasibility study at Mayo Clinic in Jacksonville, Florida. However, the study cannot

12yearplan

12yearplan 4分前

'NAH!" ??????????????????????????

was the exclamation point really necessary????????????????? !

If I understand all that previous interest discussion even half correctly I think you may have that characteristic wise and witty trading strategy still in tow and that you m

condor1

condor1 4分前

Biased Beeny, while you often make good arguing points, as to legal pleadings, I know a lot, while conversely, you have demonstrated that you know very little.
Applebaum isforming his pleading like most, if not all attorneys. There is a second cause of action after the first cause of act

havnagoodtime

havnagoodtime 5分前

It is for the benefit of whoever follows along.

My hand is raised. Thank you for your time and effort.

reachjo

reachjo 5分前

My bet is by early September, maybe sooner.

Doc logic

Doc logic 9分前

manibiotech,

Maybe we should all just focus on the manufacturing updates because until then, and getting off of OTC with partnership news, the question will be about manufacturing profitably and ability to ramp up even after an approval without that news. Approval is great but partne

Jlo32

Hey Tenkay check out Greg on LinkedIn

mrsdoubtfire

mrsdoubtfire 12分前

well as far as i know vakster stepped down

ListenToTheTrees

ListenToTheTrees 15分前

You’re entitled to your opinion, but labeling anyone who disagrees with you an “apologist” doesn’t strengthen your argument.

You say your facts haven’t been refuted, but that’s not really the issue. The debate has always been about the conclusions you draw from those facts.

goodietime

goodietime 19分前

goodietime

goodietime 19分前

TenKay

TenKay 20分前

You are forever going to be an apologist for this scam…for whatever reason. For some time I thought you were Foote because of the manner in which you started engaging on the board. I no longer believe that because I was waiting for you to jump to the $1.5 million which you never did. I don’t thin

Eths

SNTX
https://x.com/javilealoficial/status/2076084288324284708?s=46&t=6Y7w8L7iBETCgMYpIXWuzg

Eths

SNTX
https://x.com/javilealoficial/status/2076084288324284708?s=46&t=6Y7w8L7iBETCgMYpIXWuzg

Jack_White_3

Jack_White_3 24分前

Jah man. Fobi50
See ya around.

https://youtu.be/4_B4PtwE-QA?si=OsvokbUT6kP8RoPq

mascale

mascale 24分前

Company investments Potential a driver of stock value.

manibiotech

manibiotech 24分前

And you have audacity to come back and criticize others

How about theory of “ very last stage of labeling”

Lsmith500

Lsmith500 27分前

https://x.com/javilealoficial/status/2076084288324284708?s=46

WebSlinger

WebSlinger 29分前

>

And it would only cost $2,000 and fall apart in the rain!

LOL

PickStocks

PickStocks 29分前

Quote: “ ***There was an ownership Change on 3/19/2012 that canceled ALL former Preferred and Common Prospectuses along with ALL associated documents. Here take a look***
Understand POR 6 and KNOW the changes/facts in Amended POR 7 approved by the court on 2/23/2012 plus the 8K Filing on 8/1/

PickStocks

PickStocks 31分前

Quote: “ Liquidating Trust Interests (which hold the residual value of tax attributes and litigation settlements) move down the waterfall to equity holders.” all or if any money was sent to the WMILT for distribution if there was any. .. which was donated with what was left……

Eli's Gone

Eli's Gone 32分前

J0L

https://x.com/joltrades/status/2076077951469388044?s=46

ListenToTheTrees

ListenToTheTrees 37分前

Your conclusion still rests on a false premise: that if a business initiative doesn’t ultimately succeed, it must have been intended to fail.

That’s not how business, or evidence, works.

Public company history is full of products that never gained traction, acquisitions

Franklin FTSE Japan UCIT...

5.54% Call Nts 06/03/34

Rush Rare Metals

OMX Copenhagen Travel an...

Ci Global Leaders Corpor...

Bmo Brookfield Global Re...

Grupo Herdez Sab de CV (PK)

Ci Global Dividend Fund ...

Matsui Securities (PK)

Life Science Reit

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。